A possible role for familial thrombophilia in women with polycystic ovarian syndrome

Gynecological Endocrinology

Volumn 27, Issue 2, 2011, Pages 80-85

  Moini, Ashraf ^a   Sarrafion, Fariba ^b   Ziaei, Saeideh ^b   Faghihzadeh, Soghrat ^b   Arabipoor, Arezoo ^c  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TARBIAT MODARES UNIVERSITY   (Iran)

^c ROYAN INSTITUTE FOR REPRODUCTIVE BIOMEDICINE   (Iran)

Author keywords

antithrombin III; APC resistance; Familial thrombophilia; polycystic ovarian syndrome; protein C; protein S

Indexed keywords

ANTITHROMBIN III; HOMOCYSTEINE; PROTEIN C; PROTEIN S;

ACTIVATED PROTEIN C RESISTANCE; ADULT; AMINO ACID BLOOD LEVEL; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FAMILIAL DISEASE; FEMALE; FEMALE INFERTILITY; HUMAN; MAJOR CLINICAL STUDY; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; THROMBOPHILIA;

ADULT; ALGORITHMS; ANTITHROMBIN III; CASE-CONTROL STUDIES; COHORT STUDIES; FAMILY; FEMALE; FOLLICLE STIMULATING HORMONE; HUMANS; INFERTILITY, FEMALE; LUTEINIZING HORMONE; MALE; POLYCYSTIC OVARY SYNDROME; PREVALENCE; RISK FACTORS; TESTOSTERONE; THROMBOPHILIA; YOUNG ADULT;

EID: 78651484176     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513590.2010.488768     Document Type: Article

References (27)

1. Solomon CG. The epidemiology of polycystic ovary syndrome. Prevalence and associated disease risks. Endocrinol Metab Clin North Am 1999;28:247-263.
2. Goldenberg N, Glueck C. Medical therapy in women with polycystic ovarian syndrome before and during pregnancy and lactation. Minerva Ginecol 2008;60:63-75.
3. Tsanadis G, Vartholomatos G, Korkontzelos I, Avgoustatos F, Kakosimos G, Sotiriadis A, Tatsioni A, Eleftheriou A, Lolis D. Polycystic ovarian syndrome and thrombophilia. Hum Reprod 2002;17:314-319.
4. Glueck CJ, Wang P, Fontaine RN, Sieve-Smith L, Tracy T, Moore SK. Plasminogen inhibitor activity: an independent risk factor for the high miscarriage rate during pregnancy in women with polycystic ovary syndrome. Metabolism 1999;48: 1589-1595.
5. Atimo WU, Condon J, Adekanmi O, Friend J, Wilkin TJ, Archibald G. Are women with polycystic ovary syndrome resistant to activated protein C? Fertil Steril 2000;74:1229-1232.
6. Rosendaal FR. Thrombosis series: venous thrombosis: a multicausal disease. Lancet 1999;353:1167-1173.
7. Speroff L, Fritz MA. Clinical gynecologic endocrinology and infertility.7th ed. USA: A Wolters Kluwer Company; 2005. pp 1086-1088.
8. Brenner B, Mandel H, Lanir N, Younis J, Rothbart H, Ohel G, Blumenfeld Z. Activated protein C resistance can be associated with recurrent fetal loss. Br J Haematol 1997;97: 551-554.
9. Atimo W, Fox R, Condon J, Shaw S, Friend JR, Prentice AG, Wilkin TJ. Raised PAI-1 is not an independent risk factor in women with polycystic ovary syndrome. Clin Endocrinol 2000;52:487-492.
10. Hervig T, Haram K, Sandset PM. Deep venous thrombosis in pregnant women. Tidsskr Nor Laegeforen 1998;118:4093-4097.
11. Younis JS, Ohel G, Brenner B, Ben-Ami M. Familial thrombophilia-the scientific rationale for thrombophylaxis in recurrent pregnancy loss? Hum Reprod 1997;12:1389-1390.
12. Tai J, Schliamser LM, Lcibovitz Z, Ohel G, Attias D. A possible role for activated protein C resistance in patients with first and second trimester pregnancy failure. Hum Reprod 1999;14:1624-1627.
13. James AH. Prevention and management of venous thromboembolism in pregnancy. Am J Med 2007;120:S26-S34.
14. A Working Group on Behalf of the Obstetric Medicine Group of Australasia. Anticoagulation in pregnancy and the puerperium. Med J Aust 2001;175:258-263.
15. Kujovich JL. Thrombophilia and pregnancy complications. Am J Obstet Gynecol 2004;191:412-424.
16. Franks S, Gharani N, Waterworth D, Batty S, White D, Williamson R, McCarthy M. The genetic basis of polycystic ovary syndrome. Hum Reprod 1997;12:2641-2648.
17. Ghosh K, Shetty Sh, Vora S, Salvi V. Successful pregnancy outcome in women with bad obstetric history and recurrent fetal loss due to thrombophilia: effect of unfractionated heparin and low-molecular weight heparin. Clin Appl Thromb Hemost 2008;14:174-179.
18. Brenner, B. Inherited thrombophilia and pregnancy loss. Thromb Haemost 1999;82:634-640.
19. The Rotterdam ESHRE/ASRM-sponsored PCOS workshop group. Revised 2003 consensus on diagnosis criteria and longterm health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19:41-47.
20. Glueck CJ, Wang P, Bornovali S, Glodenberg N, Sieve L. Polycystic ovary syndrome, the G1691A factor V Leiden mutation, and plasminogen activator inhibitor activity: associations with recurrent pregnancy loss. Metabolism 2003;52:1627-1632.
21. Vrbíková J, Tallová J, Biciková M, Dvoráková K, Hill M, Stárka L. Plasma thiols and androgen levels in polycystic ovary syndrome. Clin Chem Lab Med 2003;41: 216-221.
22. Oktem M, Ozcimen EE, Uckuyu A, Esinler I, Pamuk B, Bayraktar N, Kulaksizoglu S, Zeyneloglu HB. Polycystic ovary syndrome is associated with elevated plasma soluble CD40 ligand, a marker of coronary artery disease. Fertil Steril 2009;91:2545-2550.
23. Gillum R. Distribution of serum total homocysteine and its association with diabetes and cardiovascular risk factors of the insulin resistance syndrome in Mexican American men: the third national health and nutrition examination survey. Nutr J 2003;5:6.
24. Sohrabvand F, Lankarani M, Golestan B, Haghollahi F, Asgarpoor L, Badamchi Z, Masoomi M, Javadi E. Serum homocysteine levels in PCOS patients versus healthy women. J Reprod Infertil 2008;9:334-341.
25. James DK, Weneri CP, Steer PhJ, Gonik B. High risk pregnancy: management options. 3th ed. USA: Elsevier Inc; 2006. pp 926-927, 938-941.
26. Glueck CJ, Sieve L, Zhu B, Wang P. Plasminogen activator inhibitor activity, 4G5G polymorphism of the plasminogen activator inhibitor 1 gene, and first- trimester miscarriage in women with polycystic ovary syndrome. Metabolism 2006;55: 345-352.
27. Glueck CJ, Aregawi D, Goldenberg N, Golnik KC, Sieve L, Wang P. Idiopatic intracranial hypertension, polycystic ovary syndrome, and thrombophilia. J Lab Clin Med 2005; 145:72-82.